All In Biotech

NDA 022014 · Padagis US

Evamist

Estradiol · Transdermal · Estrogen

Last checked: Nov 19, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Jul 27, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,701

351 Phase 3, 176 recruiting

FAERS reports

47,405

22,633 serious, 909 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and UNINTENTIONAL SECONDARY EXPOSURE TO ESTROGEN Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed and random endometrial sampling when indicated, to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions ( 5.2 )] . Cardiovascular Disorders and Probable Dementia The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of...

What it is approved for

From the label in effect Oct 29, 2024.

Evamist is an estrogen indicated for the treatment of moderate to severe vasomotor symptoms due to menopause ( 1.1 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause.

Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • EVAMIST · ESTRADIOL 1.53MG/SPRAY · SPRAY, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.

All 1,701 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,872
  • headache2,922
  • fatigue2,894
  • nausea2,892
  • off label use2,418
  • pain2,093
  • diarrhoea1,961
  • dizziness1,736
  • breast cancer female1,709
  • arthralgia1,646
  • pruritus1,568
  • rash1,545

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004524
2005571
2006402
20071,461
2008431
2009601
2010972
2011851
20121,160
2013889
20141,117
20151,923
20162,394
20172,181
20182,581
20192,912
20202,914
20212,861
20223,093
20233,561
20243,713
20255,259
20265,033

Recalls

2 FDA enforcement reports for this application.

  • Feb 21, 2023 · Class III · Ongoing

    Failed Content Uniformity Specifications: The Spray Content Uniformity (SCU) requirement for Standard Deviation did not meet the requirement at the 18-month stability time point.

  • Feb 26, 2018 · Class II · Terminated

    Defective Delivery System: Potential that cracks in the vial neck near the crimp may result in product evaporation and/or leaking and the inability to properly dispense product.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Evamist (Estradiol)

2024 spending

$376K

Beneficiaries

536

1,700 claims

Per beneficiary

$702

$16.83 per unit

View as table
YearSpending
2020$498,557
2021$498,819
2022$151,397
2023$347,020
2024$376,435

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,473 on PubMed

Sponsor: Padagis US

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.